

COPY OF PAPERS ORIGINALLY FILED

DO

| CKET NO. 1724 | ാറ പ്പെട്ട ് | PATEOT O |
|--|------------------------------------|---|
| CKET NO. 1724 | IN THE UNITED STATES PATENT AND TR | ADEMARK OFFICE |
| Applicant: | Chow et al. |) I hereby certify that this correspondence is being to deposited with the United States Postal Service and in the revisione addressed to: Assistant Commissioner for Patents, Box |
| Serial No.: | 09/815,362; Conf. No. 4078 |) Assistant Commissioner for Patenta, Box (Inventorable Change, Washington, D.C. 20231 on: |
| Filed: | March 21, 2001 | (Date of Deposit) |
| For: | COMPOUNDS AND METHOD OF | Printed Name of Person Making Deposit |
| TREATMENT HAVING AGONIST-LIKE ACTIVITY SELECTIVE | |) Per Terres |
| AT ALPHA 2B OR 2B/2C ADRENERGIC RECEPTORS | |) Signature / |
| Group Art Unit: 1626 | | 2/28/002_ |
|) | | Date of Signature |
| Examiner: | Floyd D. Higel | RECEIVED |
| | | AUG 0 6 2002 |

STATEMENT OF DARIO G. GOMEZ

TECH CENTER 1600/2900

Assistant Commissioner for Patents Washington, D.C. 20231

Dear Sir:

I, Dario G. Gomez, am an inventor of the subject matter claimed in the above-referenced patent application.

At the time the invention was made I was employed by Allergan, Inc., the parent company of the assignee Allergan Sales, Inc. I was unaware that this continuing application was filed until after the filing date, and therefore had no opportunity to advise Allergan that the inventor information, including the list of inventors, was incomplete. Thus, the incorrect naming of the inventive entity in this patent application was made without deceptive intent on my part; moreover, it is my understanding that such incorrect indication of inventors was an inadvertent error made when the patent application was filed.

Respectfully submitted,

Dated: 02/19/02



COPY OF PAPERS **ORIGINALLY FILED**

TECH CENTER 1600

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicant

Chow et al.

Serial No.:

09/815,362; Conf. No. 4078

Filed:

March 21, 2001

COMPOUNDS AND METHOD OF TREATMENT HAVING AGONIST-LIKE ACTIVITY SELECTIVE AT ALPHA 2B OR 2B/2C ADRENERGIC RECEPTORS

Group Art Unit: 1626

Examiner.

Floyd D. Higel

Art Unit:

)1626

CONSENT OF ASSIGNEE TO CORRECTION OF INVENTORSHIP

Assistant Commissioner for Patents Washington, D.C. 20231

Dear Sir.

As owner of the entire right, title, and interest in the above identified patent application, ALLERGAN hereby consents to the correction of inventorship to add Dario G. Gomez as an inventor in the above-referenced patent application. ALLERGAN'S right to take action pursuant to 37 CFR 3.73 is established in an Assignment from the inventors to ALLERGAN recorded in the Patent and Trademark Office on August 16, 1996 at Reel 8135, Frame 0552.

I, the undersigned, declare that I am authorized to make this appointment on behalf of Allergan Sales, Inc.

Respectfully submitted,

Martin A. Voet Assistant Secretary Allergan Sales, Inc. 2525 Dupont Drive Invine CA 92612